Provectus presents PV-10 Phase 2 clinical trial data for metastatic melanoma at Sydne
 

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented positive preliminary data from fully monitored study data for the entire study population of 80 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma.

More...